Literature DB >> 11752705

In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

Maria Dolores Iglesias-Ussel1, Concepción Casado1, Eloísa Yuste2, Isabel Olivares1, Cecilio López-Galíndez1.   

Abstract

Nevirapine-resistant variants were generated by serial passages in MT-2 cells in the presence of increasing drug concentrations. In passage 5, mutations V106A, Y181C and G190A were detected in the global population, associated with a 100-fold susceptibility decrease. Sequence analysis of biological clones obtained from passage 5 and subsequent passages showed that single mutants, detected in first passages, were progressively replaced in passage 15 by double mutants, correlating with a 500-fold increase in phenotypic resistance. Fitness determination of single mutants confirmed that, in the presence of nevirapine, every variant was more fit than wild-type with a fitness order Y181C>V106A>G190A>wild-type. Unexpectedly, in the absence of the drug, the Y181C resistant mutant was more fit than wild-type, with a fitness gradient Y181C>wild-type >G106A>or=V190A. Using a molecular clone in which the Y181C mutation was introduced by in vitro mutagenesis, the greater fitness of the Y181C mutant was confirmed in new competition cultures. These data exemplify the role of resistance mutations on virus phenotype but also on virus evolution leading, occasionally, to resistant variants fitter than the wild-type in the absence of the drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752705     DOI: 10.1099/0022-1317-83-1-93

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

Review 1.  Adherence-resistance relationships to combination HIV antiretroviral therapy.

Authors:  David R Bangsberg; Deanna L Kroetz; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

2.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Authors:  Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Michael J Kozal; Evguenia S Svarovskaia; Jeffrey A Johnson; Anna Maria Geretti; Karin J Metzner; Martin R Jakobsen; Katherine Huppler Hullsiek; Lars Ostergaard; Michael D Miller; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2012-12-21       Impact factor: 5.226

4.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

5.  Recombination in feline lentiviral genomes during experimental cross-species infection.

Authors:  Mary Poss; Adam Idoine; Howard A Ross; Julie A Terwee; Sue VandeWoude; Allen Rodrigo
Journal:  Virology       Date:  2006-10-12       Impact factor: 3.616

6.  Commentary on the role of treatment-related HIV compensatory mutations on increasing virulence: new discoveries twenty years since the clinical testing of protease inhibitors to block HIV-1 replication.

Authors:  Eric J Arts
Journal:  BMC Med       Date:  2012-10-03       Impact factor: 8.775

7.  In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.

Authors:  Hao Wu; Xiao-Min Zhang; Hao-Jie Zhang; Qiwei Zhang; Zhiwei Chen; Jian-Dong Huang; Shui-Shan Lee; Bo-Jian Zheng
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01-08       Impact factor: 2.205

8.  Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.

Authors:  Jessica D Church; Wei Huang; Neil Parkin; Natalia Marlowe; Laura A Guay; Saad B Omer; Philippa Musoke; J Brooks Jackson; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2009-07       Impact factor: 2.205

9.  Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.

Authors:  George K Hightower; Scott L Letendre; Mariana Cherner; Sarah A Gibson; Ronald J Ellis; Tanya J Wolfson; Anthony C Gamst; Caroline C Ignacio; Robert K Heaton; Igor Grant; Douglas D Richman; Davey M Smith
Journal:  Virology       Date:  2009-09-16       Impact factor: 3.616

10.  Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.

Authors:  Matthew S Lalonde; Ryan M Troyer; Aslam R Syed; Stanley Bulime; Korey Demers; Francis Bajunirwe; Eric J Arts
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.